Surgical Adhesion Barriers Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$4000
Buy Report View Sample

Published: December 19, 2023 Report Code: GDME1679EPD-ST

Select Item

Surgical Adhesion Barriers Pipeline Market Report Overview

Adhesions are bands of scar-like tissue that forms abnormal fibrous connections joining tissue surfaces in abnormal locations. In general, any type of transperitoneal operation can lead to the formation of adhesions ranging from minimal scarring of serosal surface to firm agglutination of nearly all structures. However, post-surgical adhesion has a considerable epidemiological and clinical impact mostly due to tissue damage caused by surgical traumas.

The surgical adhesion barriers pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials.

Key Segments ·        Gel Surgical Adhesion Barriers

·        Membrane Surgical Adhesion Barriers
Key Territories ·        The US

·        Europe

·        Japan

·        Singapore

·        Taiwan
Key Regulatory Paths ·        510(k)

·        CE

·        HSA

·        BOPA

·        NIFDS
Leading Companies ·        Actamax Surgical Materials LLC

·        Alafair Biosciences Inc

·        Anika Therapeutics Inc

·        Dalim Tissen Co Ltd

·        Duke University
Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Surgical Adhesion Barriers Pipeline Market by Segments

The key segments in the surgical adhesion barriers pipeline market are gel surgical adhesion barriers and membrane surgical adhesion barriers. As of December 2023, gel surgical adhesion barriers were the leading segment accounting for the highest number of products in the pipeline.

Surgical Adhesion Barriers Pipeline Market Analysis by Segments, 2023 (%)

Surgical Adhesion Barriers Pipeline Market Analysis by Segments, 2023 (%)

Buy the Full Report for More Segment Insights into the Surgical Adhesion Barriers Pipeline Market

Download a Free Report Sample

Surgical Adhesion Barriers Pipeline Market Segmentation by Territories

A few of the key territories for surgical adhesion barriers pipeline products are the US, Europe, Japan, Singapore, and Taiwan among others. As of December 2023, the US accounted for the highest number of pipeline products.

Surgical Adhesion Barriers Pipeline Market Analysis by Territories, 2023 (%)

Surgical Adhesion Barriers Pipeline Market Analysis by Territories, 2023 (%)

Buy the Full Report for More Territory Insights into the Surgical Adhesion Barriers Pipeline Market

Download a Free Report Sample

Surgical Adhesion Barriers Pipeline Market Segmentation by Regulatory Paths

A few of the key regulatory paths followed by the surgical adhesion barriers pipeline market are 510(k), CE, HSA, BOPA, NIFDS. As of December 2023, 510(k) was the most followed pathway for pipeline products in the market.

Surgical Adhesion Barriers Pipeline Market Analysis by Regulatory Paths, 2023 (%)

Surgical Adhesion Barriers Pipeline Market Analysis by Regulatory Paths, 2023 (%)

Buy the Full Report for More Regulatory Path Insights into the Surgical Adhesion Barriers Pipeline Market

Download a Free Report Sample

Surgical Adhesion Barriers Pipeline Market – Competitive Landscape

A few of the key companies associated with the surgical adhesion barriers pipeline market are Actamax Surgical Materials LLC, Alafair Biosciences Inc, Anika Therapeutics Inc., Dalim Tissen Co Ltd, and Duke University among others.

Alafair Biosciences Inc: Alafair Biosciences is headquartered in Austin, Texas, the US. The company is a medical device company that develops and commercialize surgical products for soft tissue repair and protection applications. The company develops products based on a non-cell adhesive hydrogel technology to protect and manage advanced wound healing. It offers VersaWrap tendon protector, an ultrathin, sutureless, bioresorbable hydrogel that protects tendon gliding by separating injured tendon from surrounding tissues.

Anika Therapeutics Inc: Anika is headquartered in Bedford, Massachusetts, the US. The company develops, manufactures, and markets therapeutic products for degenerative orthopedic diseases and traumatic conditions. It offers solutions for ortho-biologics, dermal, ophthalmic, surgical, and veterinary applications. Its major products include human and veterinary visco-supplementation, Joint implants, instrumentation devices, joint replacement solutions, regenerative and orthopedic surgical therapies, bone repair therapy, advanced wound care, and ophthalmic products.

Surgical Adhesion Barriers Pipeline Market Analysis by Companies, 2023

Surgical Adhesion Barriers Pipeline Market Analysis by Companies, 2023

Buy the Full Report for More Company Insights into the Surgical Adhesion Barriers Pipeline Market
Download a Free Report Sample

Segments Covered in the Report

Surgical Adhesion Barriers Pipeline Market Segments Outlook

  • Gel Surgical Adhesion Barriers
  • Membrane Surgical Adhesion Barriers

Surgical Adhesion Barriers Pipeline Market Territories Outlook

  • The US
  • Europe
  • Japan
  • Singapore
  • Taiwan

Surgical Adhesion Barriers Pipeline Market Regulatory Paths Outlook

  • 510(k)
  • CE
  • HSA
  • BOPA
  • NIFDS

Scope

This report provides:

  • Extensive coverage of the surgical adhesion barriers under development.

  • Exhaustive list of major pipeline products and their details, including product description, licensing and collaboration details, and other developmental activities.

  • Reviews of major players involved in the development of surgical adhesion barriers and lists all their pipeline projects.

  • Coverage of pipeline products based on various stages of development ranging from early development to approved/issued stage.

  • Key clinical trial data of ongoing clinical trials specific to pipeline products.

  • Recent developments in the segment/industry.

Reasons to Buy

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies.

  • Identify emerging players with potentially strong product portfolios and create effective counter strategies to gain a competitive advantage.

  • Identify and understand important and diverse types of surgical adhesion barriers under development.

  • Develop market-entry and market-expansion strategies.

  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline.

  • Carry out in-depth analysis of the product’s current stage of development, territory, and estimated launch date.

Actamax Surgical Materials LLC
Alafair Biosciences Inc
Anika Therapeutics Inc
ARC Medical Devices Inc
Baxter International Inc
BioActive Polymers in Lund AB
Dalim Tissen Co Ltd
Duke University
FzioMed Inc
Genzyme Corp
HydroGlaze BV
Innocoll Technologies Ltd (Inactive)
Jinwoo Bio Co Ltd
Kytogenics Pharmaceuticals Inc
Leader Biomedical Europe BV
Luna Innovations Inc
Magen OrthoMed Ltd
Maxigen Biotech Inc
Medisse BV (Inactive)
MLM Biologics Inc
PolyNovo Biomaterials Pty Ltd
Rutgers The State University of New Jersey
Seikagaku Corp
Sporogenics Pte Ltd
Stony Brook University
Toray Medical Co Ltd
Tribos LLC
TYBR Health Inc
University of North Carolina at Chapel Hill

Table of Contents

|1 Table of Contents 3

|1.1 List of Tables 5

|1.2 List of Figures 8

2 Introduction 9

2.1 Surgical Adhesion Barriers Overview 9

3 Products under Development 10

3.1 Surgical Adhesion Barriers – Pipeline Products by Stage of Development 10

3.2 Surgical Adhesion Barriers – Pipeline Products by Segment 11

3.3 Surgical Adhesion Barriers – Pipeline Products by Territory 12

3.4 Surgical Adhesion Barriers – Pipeline Products by Regulatory Path 13

3.5 Surgical Adhesion Barriers – Pipeline Products by Estimated Approval Date 14

3.6 Surgical Adhesion Barriers – Ongoing Clinical Trials 15

4 Surgical Adhesion Barriers – Pipeline Products under Development by Companies 16

4.1 Surgical Adhesion Barriers Companies – Pipeline Products by Stage of Development 16

4.2 Surgical Adhesion Barriers – Pipeline Products by Stage of Development 18

5 Surgical Adhesion Barriers Companies and Product Overview 19

5.1 Actamax Surgical Materials LLC Company Overview 19

5.1.1 Actamax Surgical Materials LLC Pipeline Products & Ongoing Clinical Trials Overview 19

5.2 Alafair Biosciences Inc Company Overview 20

5.2.1 Alafair Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 20

5.3 Anika Therapeutics Inc Company Overview 21

5.3.1 Anika Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 21

5.4 ARC Medical Devices Inc Company Overview 22

5.4.1 ARC Medical Devices Inc Pipeline Products & Ongoing Clinical Trials Overview 22

5.5 Baxter International Inc Company Overview 23

5.5.1 Baxter International Inc Pipeline Products & Ongoing Clinical Trials Overview 23

5.6 BioActive Polymers in Lund AB Company Overview 25

5.6.1 BioActive Polymers in Lund AB Pipeline Products & Ongoing Clinical Trials Overview 25

5.7 Dalim Tissen Co Ltd Company Overview 26

5.7.1 Dalim Tissen Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 26

5.8 Duke University Company Overview 29

5.8.1 Duke University Pipeline Products & Ongoing Clinical Trials Overview 29

5.9 FzioMed Inc Company Overview 30

5.9.1 FzioMed Inc Pipeline Products & Ongoing Clinical Trials Overview 30

5.10 Genzyme Corp Company Overview 32

5.10.1 Genzyme Corp Pipeline Products & Ongoing Clinical Trials Overview 32

5.11 HydroGlaze BV Company Overview 33

5.11.1 HydroGlaze BV Pipeline Products & Ongoing Clinical Trials Overview 33

5.12 Innocoll Technologies Ltd (Inactive) Company Overview 34

5.12.1 Innocoll Technologies Ltd (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 34

5.13 Jinwoo Bio Co Ltd Company Overview 35

5.13.1 Jinwoo Bio Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 35

5.14 Kytogenics Pharmaceuticals Inc Company Overview 38

5.14.1 Kytogenics Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 38

5.15 Leader Biomedical Europe BV Company Overview 39

5.15.1 Leader Biomedical Europe BV Pipeline Products & Ongoing Clinical Trials Overview 39

5.16 Luna Innovations Inc Company Overview 40

5.16.1 Luna Innovations Inc Pipeline Products & Ongoing Clinical Trials Overview 40

5.17 Magen OrthoMed Ltd Company Overview 42

5.17.1 Magen OrthoMed Ltd Pipeline Products & Ongoing Clinical Trials Overview 42

5.18 Maxigen Biotech Inc Company Overview 44

5.18.1 Maxigen Biotech Inc Pipeline Products & Ongoing Clinical Trials Overview 44

5.19 Medisse BV (Inactive) Company Overview 45

5.19.1 Medisse BV (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 45

5.20 MLM Biologics Inc Company Overview 46

5.20.1 MLM Biologics Inc Pipeline Products & Ongoing Clinical Trials Overview 46

5.21 PolyNovo Biomaterials Pty Ltd Company Overview 48

5.21.1 PolyNovo Biomaterials Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 48

5.22 Rutgers The State University of New Jersey Company Overview 49

5.22.1 Rutgers The State University of New Jersey Pipeline Products & Ongoing Clinical Trials Overview 49

5.23 Seikagaku Corp Company Overview 50

5.23.1 Seikagaku Corp Pipeline Products & Ongoing Clinical Trials Overview 50

5.24 Sporogenics Pte Ltd Company Overview 53

5.24.1 Sporogenics Pte Ltd Pipeline Products & Ongoing Clinical Trials Overview 53

5.25 Stony Brook University Company Overview 55

5.25.1 Stony Brook University Pipeline Products & Ongoing Clinical Trials Overview 55

5.26 Toray Medical Co Ltd Company Overview 56

5.26.1 Toray Medical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 56

5.27 Tribos LLC Company Overview 57

5.27.1 Tribos LLC Pipeline Products & Ongoing Clinical Trials Overview 57

5.28 TYBR Health Inc Company Overview 58

5.28.1 TYBR Health Inc Pipeline Products & Ongoing Clinical Trials Overview 58

5.29 University of North Carolina at Chapel Hill Company Overview 59

5.29.1 University of North Carolina at Chapel Hill Pipeline Products & Ongoing Clinical Trials Overview 59

6 Surgical Adhesion Barriers- Recent Developments 60

6.1 Jul 21, 2023: Seikagaku Announces Favorable Results From A Pivotal Study for Si-449, an Adhesion Barrier 60

6.2 Jun 28, 2023: Medline Announces Leadership Transition Naming New CEO and President & COO 60

6.3 May 17, 2023: S2Medical AB (publ) signs a distribution agreement for the Iranian market 61

6.4 Apr 13, 2023: S2Medical AB (publ) signs a distributor agreement in the United Arab Emirates and delivers a record order of the skin substitute Epiprotect worth about SEK 2 million 61

7 Appendix 63

7.1 Methodology 63

7.2 About GlobalData 66

7.3 Contact Us 66

7.4 Disclaimer 66

Table

Surgical Adhesion Barriers – Pipeline Products by Stage of Development 10

Surgical Adhesion Barriers – Pipeline Products by Segment 11

Surgical Adhesion Barriers – Pipeline Products by Territory 12

Surgical Adhesion Barriers – Pipeline Products by Regulatory Path 13

Surgical Adhesion Barriers – Pipeline Products by Estimated Approval Date 14

Surgical Adhesion Barriers – Ongoing Clinical Trials 15

Surgical Adhesion Barriers Companies – Pipeline Products by Stage of Development 16

Surgical Adhesion Barriers – Pipeline Products by Stage of Development 18

Actamax Surgical Materials LLC Pipeline Products & Ongoing Clinical Trials Overview 19

Actamax Adhesion Barrier – Product Status 19

Actamax Adhesion Barrier – Product Description 19

Alafair Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 20

VersaWrap Adhesion Barrier – Product Status 20

VersaWrap Adhesion Barrier – Product Description 20

Anika Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 21

HYAFF Gel – Product Status 21

HYAFF Gel – Product Description 21

ARC Medical Devices Inc Pipeline Products & Ongoing Clinical Trials Overview 22

Discrete – Product Status 22

Discrete – Product Description 22

Baxter International Inc Pipeline Products & Ongoing Clinical Trials Overview 23

ACCUREACH – Product Status 23

ACCUREACH – Product Description 23

SEPRALAP – Product Status 24

SEPRALAP – Product Description 24

BioActive Polymers in Lund AB Pipeline Products & Ongoing Clinical Trials Overview 25

BioBarrier – Product Status 25

BioBarrier – Product Description 25

Dalim Tissen Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 26

Collabarrier Anti-Adhesion Coating Material – Product Status 26

Collabarrier Anti-Adhesion Coating Material – Product Description 26

Dalim Tissen Co Ltd – Ongoing Clinical Trials Overview 27

Collabarrier Anti-Adhesion Coating Material – A Clinical Study of the Safety and Effectiveness of Ionized Atelocollagen Based Adhesion barrier(Collabarrier) for Adhesion Prevention in Spine Surgery 28

Duke University Pipeline Products & Ongoing Clinical Trials Overview 29

Intrauterine Adhesion Barrier – Product Status 29

Intrauterine Adhesion Barrier – Product Description 29

FzioMed Inc Pipeline Products & Ongoing Clinical Trials Overview 30

Oxiplex/AP – Product Status 30

Oxiplex/AP – Product Description 30

Oxiplex/IU – Product Status 31

Oxiplex/IU – Product Description 31

Genzyme Corp Pipeline Products & Ongoing Clinical Trials Overview 32

Sepraspray Adhesion Barrier – Product Status 32

Sepraspray Adhesion Barrier – Product Description 32

HydroGlaze BV Pipeline Products & Ongoing Clinical Trials Overview 33

HydroGlaze – Product Status 33

HydroGlaze – Product Description 33

Innocoll Technologies Ltd (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 34

CM004 – Product Status 34

CM004 – Product Description 34

Jinwoo Bio Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 35

HA Fabric Sheet Adhesive Barrier – Product Status 35

HA Fabric Sheet Adhesive Barrier – Product Description 36

HA Film Adhesive Barrier – Product Status 36

HA Film Adhesive Barrier – Product Description 36

Wool Adhesive Barrier – Product Status 37

Wool Adhesive Barrier – Product Description 37

Kytogenics Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 38

Adhes-X – Product Status 38

Adhes-X – Product Description 38

Leader Biomedical Europe BV Pipeline Products & Ongoing Clinical Trials Overview 39

Rebasol – Product Status 39

Rebasol – Product Description 39

Luna Innovations Inc Pipeline Products & Ongoing Clinical Trials Overview 40

Sutureless Absorbable Antiadhesion Film – Product Status 40

Sutureless Absorbable Antiadhesion Film – Product Description 40

TissuCoat – Product Status 41

TissuCoat – Product Description 41

Magen OrthoMed Ltd Pipeline Products & Ongoing Clinical Trials Overview 42

NerveShield – Product Status 42

NerveShield – Product Description 42

TendonShield – Product Status 43

TendonShield – Product Description 43

Maxigen Biotech Inc Pipeline Products & Ongoing Clinical Trials Overview 44

MaxiGel – Product Status 44

MaxiGel – Product Description 44

Medisse BV (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 45

FlexiSurge Adhesive Barrier – Product Status 45

FlexiSurge Adhesive Barrier – Product Description 45

MLM Biologics Inc Pipeline Products & Ongoing Clinical Trials Overview 46

Adhesion Barrier – Product Status 46

Adhesion Barrier – Product Description 46

Biologic Barrier Membrane – Superficial Wounds – Product Status 47

Biologic Barrier Membrane – Superficial Wounds – Product Description 47

PolyNovo Biomaterials Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 48

Anti-Adhesion Film – Product Status 48

Anti-Adhesion Film – Product Description 48

Rutgers The State University of New Jersey Pipeline Products & Ongoing Clinical Trials Overview 49

Biodegradable Film Implant – Product Status 49

Biodegradable Film Implant – Product Description 49

Seikagaku Corp Pipeline Products & Ongoing Clinical Trials Overview 50

SI-449 Adhesion Barrier System – Product Status 50

SI-449 Adhesion Barrier System – Product Description 50

Seikagaku Corp – Ongoing Clinical Trials Overview 51

SI-449 Adhesion Barrier System – A Randomized, Controlled, Pivotal Study of SI-449 Adhesion Barrier in Patients with Temporary Ileostomy 52

Sporogenics Pte Ltd Pipeline Products & Ongoing Clinical Trials Overview 53

Anti-Adhesion Barrier Film – Product Status 53

Anti-Adhesion Barrier Film – Product Description 53

Microgel Agent – Product Status 54

Microgel Agent – Product Description 54

Stony Brook University Pipeline Products & Ongoing Clinical Trials Overview 55

Bioabsorbable Membrane – Post-Operative Adhesions – Product Status 55

Bioabsorbable Membrane – Post-Operative Adhesions – Product Description 55

Toray Medical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 56

Adhesion Barrier – Product Status 56

Adhesion Barrier – Product Description 56

Tribos LLC Pipeline Products & Ongoing Clinical Trials Overview 57

Lubricin – Surgical Adhesions – Product Status 57

Lubricin – Surgical Adhesions – Product Description 57

TYBR Health Inc Pipeline Products & Ongoing Clinical Trials Overview 58

TYBR Spray – Product Status 58

TYBR Spray – Product Description 58

University of North Carolina at Chapel Hill Pipeline Products & Ongoing Clinical Trials Overview 59

Photo-Crosslinkable Nano-Patch – Product Status 59

Photo-Crosslinkable Nano-Patch – Product Description 59

Glossary 65

Figures

Surgical Adhesion Barriers – Pipeline Products by Stage of Development 10_x000D_

Surgical Adhesion Barriers – Pipeline Products by Segment 11_x000D_

Surgical Adhesion Barriers – Pipeline Products by Territory 12_x000D_

Surgical Adhesion Barriers – Pipeline Products by Regulatory Path 13_x000D_

Surgical Adhesion Barriers – Pipeline Products by Estimated Approval Date 14_x000D_

Surgical Adhesion Barriers – Ongoing Clinical Trials 15_x000D_

Frequently asked questions

Surgical Adhesion Barriers Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies standard reports
Currency USD
$4,000

Can be used by individual purchaser only

Most Popular
$8,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$12,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Surgical Adhesion Barriers Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Surgical Adhesion Barriers reports
Medical Devices
New
PTA Peripheral DCB Catheters Pipeline by Development Stages, Segments, Region…
$4,000 | March 2024
Medical Devices
New
PCR Systems Market Size by Segments, Share, Regulatory, Reimbursement, Installed…
$7,500 | March 2024
Medical Devices
New
Immunochemistry Analyzers Market Size by Segments, Share, Regulatory, Reimbursement, Installed…
$7,500 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Surgical Adhesion Barriers Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies in real time.

  • Access a live Surgical Adhesion Barriers Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more